Literature DB >> 10740573

Larva therapy in wound management.

M Courtenay1, J C Church, T J Ryan.   

Abstract

The use of maggots for wound debridement has a long history and has lately gained ground in several countries. We collected prospective data to examine the current use of larva therapy (LT) in the UK. Quantitative information was collected on 70 patients treated in nine hospitals. LT is used primarily to treat leg ulcers and generally involves three applications of larvae at two to three day intervals. This method is judged effective in wound debridement and promotes the growth of granulation tissue. Wound exudate, odour, infection and pain are all reduced by the treatment. Adverse reactions are infrequent but include pain, bleeding, pyrexia and influenza-like symptoms. Prevention of hospital admission and surgery, reduced need for antibiotics and reduced hospital stay are all identified as outcomes of LT. The nurse practitioners who used LT believed it to have an important role in wound management. A randomized clinical trial, comparing LT with other debriding agents, is required for evaluation of cost effectiveness.

Entities:  

Mesh:

Year:  2000        PMID: 10740573      PMCID: PMC1288068          DOI: 10.1177/014107680009300206

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  15 in total

1.  [Wound debridement and treatment of ulcus cruris. Conservative and operative therapeutic procedures].

Authors:  H Stege; R Mang
Journal:  Hautarzt       Date:  2003-11       Impact factor: 0.751

Review 2.  Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential.

Authors:  Iain S Whitaker; Christopher Twine; Michael J Whitaker; Mathew Welck; Charles S Brown; Ahmed Shandall
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

3.  Maggot excretions/secretions induces human microvascular endothelial cell migration through AKT1.

Authors:  Shou-yu Wang; Kai Wang; Yi Xin; De-cheng Lv
Journal:  Mol Biol Rep       Date:  2009-09-16       Impact factor: 2.316

4.  Lucilia sericata chymotrypsin disrupts protein adhesin-mediated staphylococcal biofilm formation.

Authors:  Llinos G Harris; Yamni Nigam; James Sawyer; Dietrich Mack; David I Pritchard
Journal:  Appl Environ Microbiol       Date:  2012-12-07       Impact factor: 4.792

5.  Evaluation of conventional therapeutic methods versus maggot therapy in the evolution of healing of tegumental injuries in Wistar rats with and without diabetes mellitus.

Authors:  Franciéle Souza Masiero; Patricia Jacqueline Thyssen
Journal:  Parasitol Res       Date:  2016-03-15       Impact factor: 2.289

Review 6.  National Athletic Trainers' Association Position Statement: Management of Acute Skin Trauma.

Authors:  Joel W Beam; Bernadette Buckley; William R Holcomb; Mario Ciocca
Journal:  J Athl Train       Date:  2017-01-16       Impact factor: 2.860

7.  Sterilization of blow fly eggs, Chrysomya megacephala and Lucilia cuprina, (Diptera: Calliphoridae) for maggot debridement therapy application.

Authors:  Kwankamol Limsopatham; Phadungkiat Khamnoi; Kabkaew L Sukontason; Dheerawan Boonyawan; Tarinee Chaiwong; Kom Sukontason
Journal:  Parasitol Res       Date:  2017-03-30       Impact factor: 2.289

8.  Maggot debridement therapy for peripheral arterial disease.

Authors:  Kimihiro Igari; Takahiro Toyofuku; Hidetoshi Uchiyama; Shinya Koizumi; Koji Yonekura; Toshifumi Kudo; Masatoshi Jibiki; Norihide Sugano; Yoshinori Inoue
Journal:  Ann Vasc Dis       Date:  2013-05-30

9.  Maggot debridement therapy of infected ulcers: patient and wound factors influencing outcome - a study on 101 patients with 117 wounds.

Authors:  Pascal Steenvoorde; Cathrien E Jacobi; Louk Van Doorn; Jacques Oskam
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

10.  Adjunct methods of the standard diabetic foot ulceration therapy.

Authors:  Dariusz Waniczek; Andrzej Kozowicz; Małgorzata Muc-Wierzgoń; Teresa Kokot; Elżbieta Swiętochowska; Ewa Nowakowska-Zajdel
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.